Sutro Biopharma

Focused on creating next-generation cancer and autoimmune therapeutics

Sutro Biopharma is a drug discovery, development, and manufacturing company. Using precise protein engineering and rational design, the company is advancing next-generation oncology therapeutics. Sutro’s proprietary and integrated cell-free protein synthesis platform XpressCF® and site-specific conjugation platform XpressCF+™ led to the discovery of STRO-001 and STRO-002, Sutro’s first two internally-developed antibody-drug conjugates (ADCs).

Status
NASDAQ: STRO
Year of Investment
2020
Strategy
Life Sciences
Location
South San Francisco, California